This study evaluated the efficacy of betamethasone zinc oxide (BZO), a topical compound containing zinc oxide and betamethasone G (a combination of Betamethasone 0.1% +gentamicin sulphate 0.1%, It is an antibiotic). Four formulations with varying concentrations of zinc oxide (6.25, 12.5, 18.75 and 25 gm) with 15 gm of Betamethasone G (w/w) were applied to laboratory-induced wounds in mice for 30 days to evaluate their therapeutic effects. The aim of this work was to mix compounds to find a suitable and effective formula and obtaining a compound with lower cost and study the effect of adding zinc oxide on the compound. The results showed that BG-Z significantly improved wound healing, with zinc oxide formulation (Sample 4) showing the highest therapeutic efficacy. Comparative clinical trials revealed that wounds treated with BG-Z healed faster, showed less inflammation, and had lower infection rates compared to those treated with betamethasone G alone. Physical stability testing confirmed the integrity of the formulation, with no change in color, texture, or activity at different temperatures. These results highlight betamethasone G zinc as a cost-effective and highly effective treatment for dermatological diseases, as it improves wound healing and enhances its anti-inflammatory and antimicrobial properties. This study provides a promising basis for the development of advanced topical treatments for wound management and the treatment of dermatological diseases.
Ali Hussein Mustafa AL-Obaidi (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: